Multinational healthcare company Sanofi (NASDAQ: SNY) announced having inked a licensing agreement with biotechnology company developing therapeutics and technologies to treat neurological and mental illness Terran Biosciences.
More details on the licensing agreement are still scanty but the deal included two of Sanofi’s central nervous system (CNS) assets. Citing a press release by Terran, these assets ‘generated 4 investigational new drug applications and over 104 clinical studies involving more than 15,000 subjects.’
“We are grateful to the Sanofi team for entrusting us to continue the development of these late-stage therapeutics, which we believe have the potential to transform the paradigm in neuropsychiatry,” said the founder and CEO of Terran, Dr. Sam Clark.
In recent times, Terran has been making strides in the psychedelics space. Early last month, the company acquired a portfolio of central nervous system assets from clinical stage biopharmaceutical company developing innovative medicines with unique healing properties to address the needs of patients with chronic diseases Concert Pharmaceuticals Inc. (NASDAQ: CNCE).
A few days later, Terran announced having entered into an exclusive agreement with Columbia University for the rights to the university’s proprietary CNS biomarker platform.
About two weeks ago, Terran also signed an agreement with Blumentech to purchase its full patent portfolio as well any accompanying data.
